Join
Live feed
·
PRReleasevia Quantisnow
Iterum Therapeutics plc logo

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

ByQuantisnow·Wall Street's wire, on your screen.
ITRM· Iterum Therapeutics plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ITRM (Iterum Therapeutics plc) and more on Quantisnow.